Literature DB >> 20663933

Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway.

René Handrick1, Teona Ontikatze, Kerstin-Daniela Bauer, Florian Freier, Amelie Rübel, Jan Dürig, Claus Belka, Verena Jendrossek.   

Abstract

The sesquiterpene lactone dihydroartemisinin (DHA), a semisynthetic derivative of the herbal antimalaria drug artemisinin, is cytotoxic to human tumor cells. Treatment of Jurkat T-lymphoma cells with DHA induced a breakdown of the mitochondrial transmembrane potential, release of cytochrome c, activation of caspases, and DNA fragmentation indicative of apoptosis induction. Although the absence of FADD or caspase-8 did not alter apoptosis rates in Jurkat cells, overexpression of dominant-negative caspase-9 or of antiapoptotic Bcl-xL or Bcl-2 largely decreased the cytotoxicity of DHA, demonstrating a role of the intrinsic death pathway. The proapoptotic Bcl-2 effector protein Bak and the Bcl-2 homology domain 3-only protein NOXA turned out to be important mediators of DHA-induced apoptosis in Jurkat cells. DHA treatment triggered the expression of NOXA and the activation of Bak. Furthermore, DHA-induced apoptosis was completely abrogated by loss of Bak and largely reduced in cells with siRNA-mediated downregulation of Bak or NOXA. Proapoptotic signaling of DHA also involved the formation of reactive oxygen species and membrane oxidation. Pretreatment with the lipophilic radical scavenger vitamin E or the hydrophilic radical scavengers glutathione and N-acetylcysteine reduced DHA-induced membrane oxidation and apoptosis, respectively. Oxidative changes also occurred in cells with disruption of the mitochondrial death pathway, suggesting a role of reactive oxygen species and oxidative membrane changes in death signaling upstream of the mitochondria. Interestingly, DHA increased the cytotoxic action of ionizing radiation and of the death receptor agonist tumor necrosis factor-related apoptosis-inducing ligand in Jurkat cells, suggesting a potential benefit of DHA in combined treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663933     DOI: 10.1158/1535-7163.MCT-10-0051

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  29 in total

1.  The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials.

Authors:  Amy E Mercer; Ian M Copple; James L Maggs; Paul M O'Neill; B Kevin Park
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

2.  Effect of dihydroarteminin combined with siRNA targeting Notch1 on Notch1/c-Myc signaling in T-cell lymphoma cells.

Authors:  Lanfen Huo; Wenwen Wei; Shaoling Wu; Xindong Zhao; Chunting Zhao; Hongguo Zhao; Lingjie Sun
Journal:  Exp Ther Med       Date:  2018-01-23       Impact factor: 2.447

3.  Dihydroarteminsin-induced apoptosis is not dependent on the translocation of Bim to the endoplasmic reticulum in human lung adenocarcinoma cells.

Authors:  Min Chen; Tong-sheng Chen; Ying-ying Lu; Cheng-yi Liu; Jun-le Qu
Journal:  Pathol Oncol Res       Date:  2012-03-07       Impact factor: 3.201

Review 4.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

5.  BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Authors:  Kristopher A Sarosiek; Xiaoke Chi; John A Bachman; Joshua J Sims; Joan Montero; Luv Patel; Annabelle Flanagan; David W Andrews; Peter Sorger; Anthony Letai
Journal:  Mol Cell       Date:  2013-09-26       Impact factor: 17.970

6.  The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis.

Authors:  Christopher M Cabello; Sarah D Lamore; Warner B Bair; Shuxi Qiao; Sara Azimian; Jessica L Lesson; Georg T Wondrak
Journal:  Invest New Drugs       Date:  2011-05-06       Impact factor: 3.850

7.  Rapamycin promotes the anticancer action of dihydroartemisinin in breast cancer MDA-MB-231 cells by regulating expression of Atg7 and DAPK.

Authors:  Qiujun Liu; Xianyao Zhou; Chuan Li; Xuemei Zhang; Chang Long Li
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

8.  The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells.

Authors:  Rui Cheng; Cen Li; Chaoyang Li; Ling Wei; Lei Li; Yang Zhang; Yachao Yao; Xiaoqiong Gu; Weibin Cai; Zhonghan Yang; Jianxing Ma; Xia Yang; Guoquan Gao
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-15       Impact factor: 4.799

9.  Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Amit Budhraja; Meghan E Turnis; Michelle L Churchman; Anisha Kothari; Xue Yang; Haiyan Xu; Ewa Kaminska; John C Panetta; David Finkelstein; Charles G Mullighan; Joseph T Opferman
Journal:  Clin Cancer Res       Date:  2017-10-03       Impact factor: 12.531

Review 10.  Artemisinin-type drugs for the treatment of hematological malignancies.

Authors:  R I Mancuso; M A Foglio; S T Olalla Saad
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-03       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.